Lv1
40 积分 2025-07-04 加入
An immunogenic personal neoantigen vaccine for patients with melanoma
23天前
已完结
错配修复缺陷与完整的结直肠癌相关基因 体细胞突变差异分析
2个月前
已完结
Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)
9个月前
已完结
Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC)
10个月前
已关闭
Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC)
10个月前
已关闭
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
10个月前
已完结
Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer
10个月前
已完结
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer : the 'BRAF BeCool' study
10个月前
已完结
Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study
10个月前
已完结
皖公网安备34019202002308
